[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367804-105":59,"doc-detail-367804-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","simvastatin-mediated-molecular-mechanisms-underlying-the-growth-inhibition-of-testicular-leydig-tumour-cells","Simvastatin-Mediated Molecular Mechanisms Underlying the Growth Inhibition of Testicular Leydig Tumour Cells","","Leydig cell tumours (LCTs) are rare testicular neoplasms, with malignant forms often aggressive and lacking effective targeted therapies. The study investigated whether statins could inhibit LCT growth, building on evidence for the central role of the insulin-like growth factor 1 (IGF1)/IGF1 receptor (IGF1R) signalling axis. Results show that simvastatin reduces proliferation of R2C and LC540 rat Leydig tumour cells, induces reactive oxygen species accumulation, triggers apoptosis, and causes cell-cycle arrest at the G1 phase. Mechanistically, simvastatin suppresses isoprenoid farnesyl pyrophosphate (FPP) formation and decreases IGF1R expression, disrupting IGF1R pathway signalling. Notably, simvastatin synergises with cisplatin to further reduce tumour cell proliferation, supporting its potential as an anticancer agent and possible adjuvant in LCT chemotherapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/simvastatin-mediated-molecular-mechanisms-underlying-the-growth-inhibition-of-testicular-leydig-tumour-cells/367804/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/simvastatin-mediated-molecular-mechanisms-underlying-the-growth-inhibition-of-testicular-leydig-tumour-cells/367804.png","ImageObject",300,407,{"name":92,"@type":93},"Elsa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-21","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are Leydig cell tumours difficult to treat, and what is the study’s goal?","Question",{"text":112,"@type":113},"Malignant LCTs are aggressive and show poor response to existing chemotherapy or radiation. The study aims to test whether simvastatin can inhibit LCT growth and clarify the underlying molecular mechanisms.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does simvastatin affect Leydig tumour cells in the experiments?",{"text":117,"@type":113},"Simvastatin reduces cell proliferation, causes G1-phase cell-cycle arrest, accumulates reactive oxygen species, and induces apoptosis in R2C and LC540 rat Leydig tumour cells.",{"name":119,"@type":110,"acceptedAnswer":120},"What molecular pathway changes explain simvastatin’s anti-tumour effects?",{"text":121,"@type":113},"Simvastatin prevents farnesyl pyrophosphate (FPP) formation and decreases IGF1R expression, leading to breakdown of IGF1R signalling and impaired tumour cell survival and growth.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367804,1790194776,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137455077381,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Journal of Cellular and Molecular Medicine  \nORIGINAL ARTICLE  OPEN ACCESS   \nSimvastatin-Mediated Molecular Mechanisms Underlying the Growth Inhibition of Testicular Leydig Tumour Cells  \nArianna De Luca1 | Lucia Zavaglia1 | Lucia Francesca Vuono1 | Francesca Giordano1 | Davide La Padula2 | Francesca De Amicis1 | Vincenzo Pezzi1  | Adele Chimento1   \n1Department of Pharmacy and Health and Nutritional Sciences, University of Calabria, Rende, Cosenza, Italy | 2Department of Health Sciences,“Magna Graecia” University of Catanzaro, Catanzaro, Italy  \nCorrespondence: Vincenzo Pezzi ([v.pezzi@unical.it](v.pezzi@unical.it)) | Adele Chimento ([adele.chimento@unical.it](adele.chimento@unical.it))  \nReceived: 30 May 2025 | Revised: 29 July 2025 | Accepted: 1 August 2025  \nFunding: This work was supported by University of Calabria (ex 60%-MUR) .  \nKeywords: apoptosis | cell cycle arrest | insulin-like growth factor 1 receptor | isoprenoids | Leydig cell tumour | simvastatin  \nABSTRACT  \nLeydig cell tumours (LCTs) are uncommon stromal neoplasms of the testis, accounting for less than 3% of all gonadal cancers. Most of them are benign, but the malignant ones are very aggressive without specific effective treatment. Several studies reported pharmacologic insight into the use of statins as anti-tumour agents, but their efficacy on LCTs has not been investigated. Previously, we emphasised the central role of insulin-like growth factor 1 (IGF1)/insulin-like growth factor 1 receptor (IGF1R) signalling in Leydig cell tumorigenesis; here, we showed that simvastatin reduces cell proliferation, determines cell cycle arrest at the G1 phase, and induces reactive oxygen species (ROS) accumulation and apoptosis in R2C and LC540 rat Leydig tumour cells. Furthermore, it prevents isoprenoid farnesyl pyrophosphate (FPP) formation and decreases IGF1R expression, leading to the breakdown ofthe IGF1R signalling pathway. Importantly, we observed that simvastatin synergised with cisplatin in reducing tumour cell proliferation. Collectively, these data suggest that simvastatin is a potential anticancer drug capable of counteracting LCT growth, and it could be proposed as an adjuvant for chemotherapy in LCT treatment.  \n1 | Introduction  \nLeydig cell tumours (LCTs) are rare neoplasms of sex cord/gonadal stromal origin that are mainly characterised by interstitial steroid secretion [1, 2] . These tumours account for about 3% of all testicular neoplasms, with two peaks of incidence: one during the prepubertal age between 5 and 10 years, the other in adulthood between 30 and 60 years old [1] . LCT is usually benign, while an estimated 10%–15% metastasizes and are malignant [3] . Mainly, LCT treatment is surgical resection for both benign and malignant pathological forms; the therapeutic options are very limited and make use of radiotherapy and chemotherapy [1, 3] . Unfortunately, malignant LCTs do not have a good prognosis, respond poorly to chemotherapy or radiation, and they are characterised by an average survival of about 2 years [3] . Although  \nthe LCT aetiology is still unknown, in vitro and in vivo studies indicate that overexpression of aromatase, the enzyme responsible for oestrogen synthesis, plays a significant role in Leydig cell tumorigenesis [4–6]. Furthermore, it has also been observed that LCT cell proliferation is supported by an enhanced expression of insulin-like growth factor 1 (IGF1) signalling pathway components and by the cooperation between estradiol (E2) and IGF1 [5] .  \nIt knows that Leydig cells synthesise steroid hormones starting from cholesterol and that excessive cholesterol accumulation can disrupt their function and potentially lead to impaired steroidogenesis [7] . It is also reported that cancer cells display constitutively elevated levels of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMG-CoAR), resulting in  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits","cbCaieMHg79IuUor","https://ap.wps.com/l/cbCaieMHg79IuUor","pdf",3417304,15,"English","# Introduction\n## Background on Leydig cell tumours and treatment constraints\n## IGF1/IGF1R signalling and steroidogenesis involvement\n## Rationale for statins and the mevalonate pathway\n# Abstract","[{\"question\":\"Why are Leydig cell tumours difficult to treat, and what is the study’s goal?\",\"answer\":\"Malignant LCTs are aggressive and show poor response to existing chemotherapy or radiation. The study aims to test whether simvastatin can inhibit LCT growth and clarify the underlying molecular mechanisms.\"},{\"question\":\"How does simvastatin affect Leydig tumour cells in the experiments?\",\"answer\":\"Simvastatin reduces cell proliferation, causes G1-phase cell-cycle arrest, accumulates reactive oxygen species, and induces apoptosis in R2C and LC540 rat Leydig tumour cells.\"},{\"question\":\"What molecular pathway changes explain simvastatin’s anti-tumour effects?\",\"answer\":\"Simvastatin prevents farnesyl pyrophosphate (FPP) formation and decreases IGF1R expression, leading to breakdown of IGF1R signalling and impaired tumour cell survival and growth.\"}]","Simvastatin-Mediated Molecular Mechanisms Underlying the Growth Inhibition of Testicular Leydig Tumour Cells | PDF",1790172747,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/780f196a218b51afbc4cc5b78bf5cb9c.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8e5c885de81f3a246035882badb60db.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/562f39ba85999636586bbf65dc24c877.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94628e855e3245089220eb10c56cc7c0.webp",980,1287]